QuickLinks -- Click here to rapidly navigate through this document
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F: ý Form 40-F: o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes: o No: ý
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes: o No: ý
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: o No: ý
Page 1 of 6
Enclosures: Invitation to full-year 2002 results presentation, to be held on Thursday, January 23, 2003.
|
Investor Relations | Novartis International AG CH-4002 Basel Switzerland Karen J Huebscher, PH.D. Tel +41 61 324 8433 Nafida Bendali Tel +41 61 324 3514 Sabine Moravi, MBA Tel + 41 61 324 8989 Silke Zenter Tel +41 61 324 8612 Francisco Bouzas Tel +41 61 324 8444 Fax+ 41 61 324 8844 Internet Address: http://www.novartis.com |
Invitation
–Full Year Results 2002–
The Executive Committee of Novartis has great pleasure in inviting you to the presentation of the 2002 results and business developments. The meeting will take place on
Thursday, January 23, 2003
14:00 at the
Messe in Zurich
Wallissellenstr. 49
Zurich, Switzerland
Following the presentation, there will be an opportunity to meet Management over cocktails and a light buffet meal.
Please Note:
Investors will be able to follow the presentation live by a telephone line and on the Internet on January 23, 2003. Internet information will be available on line as from January 15, 2003.
Page 2 of 6
- Full Year Results 2002 webcast and dial-in numbers -
Webcast
If you wish to follow our Full Year Results presentation as a webcast on the Internet, please use the following link: http://www.novartis.com/investors (available only from January 15, 2003 onwards, for tests).
Dial in
If you prefer to dial into the conference through a telephone line we also offer the following dial-in numbers. The presentations will be available on the website about 2 hours prior to the start of the event for download.
| Time: | Advisable: dial-in 15 minutes before | |||
| 2.00 p.m. | Switzerland | |||
| 1.00 p.m. | UK | |||
| 8.00 a.m. | New York | |||
| Dial-in numbers: | +41 91 610 56 00 | Europe and ROW | ||
| +800 2467 8700 | Toll free Europe, ROW and Japan (for Japan one of the following network providers Japan Telecom, JDC & KDD is required) | |||
| +44 207 866 41 11 | UK | |||
| +1 800 860 2442 | (Tollfree USA) | |||
| +1 866 519 5086 | (Tollfree Canada) | |||
| +1 866 519 5087 | (Tollfree Mexico) |
Playback for 72 hrs after the call commences
| Date: | Thursday, January 23, 2003 | |
| Time: | 6.00 p.m. (Switzerland) | |
| 5.00 p.m. (UK) | ||
| 12.00 p.m. (New York) | ||
| Dial-in numbers: | +41 (0) 848 72 25 00 Europe | |
| +1 877 344 75 29 USA | ||
| Code: | 539# |
Page 3 of 6
- Program -
| 13:30 | Door opening | |
| 14:00 | Start of conference | |
Speakers: |
||
| D. Vasella | Introduction | |
| T. Ebeling | Pharmaceuticals | |
| D. Epstein | Oncology | |
| P. Choffat | Consumer Health | |
| C. Seiwald | Generics | |
| R. Breu | Finance | |
| D. Vasella | Outlook | |
| Q&A |
Followed by cocktails and a light buffet meal
Page 4 of 6
o I will attend the Zurich Presentation on January 23, 2003
o I will follow the presentation on the Internet
o I will follow the presentation by telephone conference
First name |
||
Last name |
||
Company |
||
Address |
||
Fax |
||
Please send your response by mail or fax no later than January 20, 2003 to:
Novartis International AG
Susanne Lüdi
Lichtstrasse 35
CH-4002 Basel
Fax # +41 61 324 84 44
E-mail: susanne.luedi@group.novartis.com
Page 5 of 6
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NOVARTIS AG | |||
Date: January 14, 2003 |
By: |
/s/ MALCOLM B. CHEETHAM Name: Malcolm B. Cheetham Title: Head Group Financial Reporting and Accounting |
|
Page 6 of 6
SIGNATURES